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A novel approach to post-mastectomyradiation therapy
usingscannedproton beams
Running title: Post-mastectomyradiationtherapyusingIMPT
Abstract
Purpose:Post-mastectomyradiation therapy (PMRT) is currently offered at the
institution using proton pencilbeam scanning(PBS) with intensity modulation,
achievingcompletetargetcoverageof chestwall and all nodalregionsand reduced
doseto thecardiacstructures.Thiswork presentsthecurrentmethodologyin placefor
suchtreatment,andtheon-going effort for its improvements.
Materials and methods:A singlePBSfield is optimizedto ensureappropriatetarget
coverageandheart/lungsparing,usingan in-housedevelopedprotonplanningsystem
with thecapabilityof multi-criteriaoptimization(MCO). Thedoseto chestwall skin is
controlledas a separateobjectivein the optimization.Surfaceimagingis usedfor
setupas it is a suitablesurrogatefor superficialtargetvolumes.In orderto minimize
theeffectof beamrangeuncertainties,therelative protonstoppingpowerratio (RSP)
of the material in breastimplantswas determinedthrough separatemeasurements.
Phantommeasurementswere also performedto validatethe accuracyof skin dose
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calculation in the treatment planning system. Additionally, the treatment
planningrobustnesswas evaluatedagainstsetupperturbationsand patientbreathing
motion.
Results:PBSPMRT planningresultsin appropriatetargetcoverageaswell asorgan
sparing, comparableto treatmentsby passive scattering (PS) beams, but much
improvedin nodalcoverageandcardiacsparingcomparedto conventionaltreatments
by photon/electronbeams.The overall treatmenttime is much shorterthan PS,and
alsoshorterthanconventionalphoton/electrontreatment.Theaccuracyof theskin dose
calculationby the planningsystemis within ±2 %. The treatmentwas shownto be
adequatelyrobust against both setupuncertaintiesand patient breathing motion,
resultingin clinically satisfyingdosedistributions.
Conclusions:Over 25 PMRT patients have been successfully treated at the
institutionusingsinglePBSfields.Themethodologyandrobustnessof both thesetup
andthetreatmentweredemonstrated.
1 Introduction
Radiationtherapyhasbeenaneffectivetool in themanagementof breastcancer[1].
There are, however,concernsof late cardiac effects due to this treatment[2-8].
Minimizing the dose to the heart has been the focus of various treatment
improvementsincluding the use of heart blocks, CT-based planning, intensity
modulation, etc. [9]. Breath holding is one of the most effective techniquesin
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reducingthevolumeof cardiactissuesfor conventionalphotontherapyusingtangent
fields andis currentlypracticedin manyinstitutions[10,11], eventhoughits efficacy
hasrecentlybeenquestioned[12].
Despitestheseefforts, target volumescannotbe fully coveredwhile avoiding the
cardiactissuesfor manypatients.This is true for post-mastectomyradiationtherapy
(PMRT) with involvedinternalmammarynodes(IMN) for patientswith unfavorable
cardiacanatomy.The standardPMRT treatmenttechniqueusesa combinationof
photon/electronbeamswith up to five fields involving multiple field matching.The
optimization of such complex plans usually takes tremendousefforts in order to
balance between IMN coverage, heart dose, hot and cold spots.
Thedistinctivephysicalpropertiesof theprotonbeam,i.e. theBraggpeak,offersnew
possibilitiesin meetingthe challengesof PMRT. Severaltreatmentplanningstudies
have demonstratedsignificant dosimetricadvantagesfor reducingheart and lung
doseswhile improving targetcoverage[13-17]. Thus,a proton PMRT clinical trial
wasstartedat theinstitutionandearly outcomesshowedthat the treatmentwaswell
tolerated[18].
A first setof patientswastreatedwith enfacepassivelyscattered(PS)protonbeams.
While the treatmentsachievedtheprimarygoalsof minimizing thedoseto theheart
andlungs,andadequatelycoveringthechestwall andinvolvednodes,severalaspects
of the treatmentwere less than ideal. The largesteffective field size (± 2 % dose
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homogeneity)for a PSbeamis 22 cm in diameter.Most patientsthereforerequired
abuttingfields, one for chestwall/IMN and one for the superiornodal targets.The
matchlinebetweenthe two fields hadto befeathered,requiringtwo setsof hardware
(apertureand compensators).The overall treatmentgenerally took  30 minutes.
Moreover, the lack of intensity modulation resulted in full skin dose and dose
heterogeneities.
Protonpencilbeamscanning(PBS)is graduallybecomingavailablein protontherapy
centersworldwide.Two of themostdistinctivefeaturesof PBS,intensitymodulation
andlargertreatmentfield size,arecritical elements for improvingprotonPMRT.This
work describesthe institutionPBSPMRT treatmenttechnique,its validation,aswell
astheongoingeffortsperformedto ameliorateits delivery.
2 Materials and methods
2.1Patient setupand CT scanning
The PMRT patients were positioned on a breast board used for conventional
photon/electrontreatmentwith botharmsup abovetheirhead.Thebreastboardangle
wasraisedto its limit to helpwith thesurfaceimagingsystemusedfor patientsetup.
Various improvementswere deployedin order to minimize setuppositionerrors:a
head& neckheadcupwasusedto bettercontrol theneckposition;handgrips anda
chinstrapwereprovidedto furtherimmobilizethearmandchinpositions.Figure1(a)
showsthe setupat the institution with the patient’s armsraisedabovetheir head.
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Figure1(b) alsoshowsthe samepatientin a arm down position.For somepatients,
this akimbopositionwas the only choicefor radiotherapydue to someimmobility
factors. As later discus ed, this position presents convenient aspects.
A helicalCT scanof thepatientat quietrespirationwasacquiredusinga GE Medical
Systems™LightSpeedRT16or DiscoveryCTR590RTat 140 kV and 500 mA with
2.5mmslicethickness.
2.2Treatment planning
Similar delineationof thetargetvolumesandorgansat risk (OAR) areperformedfor
PBS treatmentas for conventionalphoton therapy. The target (CTV) is usually
composedof the wholechestwall andlymph nodesconsideredat risk for harboring
disease(axillary, supraclavicular,internalmammary).
Planningobjectivesaregenerallydefinedasfollow:
  45 Gy(RBE)to the chestwall andall nodesfollowed by a 5.4 Gy(RBE)boostto the chestwall and
internalmammarynodes(IMN)
  48Gy(RBE)maxdoseto thechestwall’s skin(  3 mmsuperficial)
  3 Gy(RBE)maxdoseto theleft anteriordescendingcoronaryartery(LAD)
  5 Gy(RBE)maxdoseto theheart’sleft ventricle
    1 Gy(RBE)meanheartdose
    15% V20 for eachlung
  42Gy(RBE)maxdoseto thethyroid
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  40Gy(RBE)maxdoseto theesophagus
RBE(relativebiologicaleffectiveness)correspondsto theratioof x- or   -rayabsorbed
dose(Gy) to thatof a modality(Gy(RBE))to obtainthesamebiologicalendpoint.A
RBEvalueof 1.1is consideredfor protons[19].
TPS-name, an in-house treatment planning software (TPS) with multi-criteria
optimization(MCO) wasused.PMRT plansuseda PBSfield at a givengantryangle
(30   from vertical).Beamspotswereplacedon a fixed-sizegrid, extending15 mm
aroundthe assignedtarget volume,with spotsspacedat one sigma(spot size). In
depth,scanninglayerswerespacedby 0.8× thedistal80 % Braggpeakwidth.Dueto
machinelimitations, an 8 cm range shifter was used to appropriatelyreach the
superficialtargets.theinstitution’s clinical machinepresentsa9 to 16 mmspotsizeas
a function of energy. Pareto-optimal plans were generatedto meet the given
constraints[20]. Finally, the setof Pareto-optimalplanswerenavigatedto a desired
state.
2.3Beamrangeuncertainty
Beam range uncertainty due to inaccurateCT HU to proton stopping power
conversionis alwaysa concernandthe usualpracticeat the institution is to addan
extra3.5 % to the beamrangeto headoff the potentialundershooting.For patients
withoutbreastimplant,thechestwall targetvolumesareusuallyveryshallowwith the
requiredbeamrangeat 3 cm or less.Theassociateduncertaintyis thusonly arounda
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millimeter and can be practically ignored,beingcomparableto uncertaintiesin CT
scanning,contouring, etc. For patientswith breastimplants, the deepertreatment
range required to reach the chest wall could result in significantly larger range
uncertaintiesand potentially overshootinto the lung and cardiactissues.Phantom
measurementswere therefore performedin order to accuratelyassessthe relative
protonrelativestoppingpowerratio (RSP)of theexactmaterialusedinsidethebreast
implant.During planning,thebreastimplantswerecontouredandassignedtheexact
RSPvalue basedon thosephantommeasurements.With the contributionfrom the
breastimplantsentirelyeliminated,theresultantrangeuncertaintycontainsonly those
from the real chestwall tissueandis thusthe sameasthosefor the chestwall only
treatments.The measurementechniquesof determiningthe RSP values for the
variousimplantsanddetailedanalysisof thedatawill bereportedseparately.
Anotherpossiblesourceof rangeuncertaintyis thedaily variationsin thepositionof
the breast implant relative to the rest of the body. However, for patient with
reconstructivesurgery,only thosewith breastimplantswereallowedfor PBSPMRT
dueto theextremelylimitedmobility of suchimplants.
2.4Skin dose
Unlike photonbeams,protonbeamsdo nothavedosebuild upsat theskin surface.It
is naturally a concern if proton PMRT could increasechest wall skin toxicity,
althoughno suchincreasewasobservedfor the first grouppatientstreatedby passive
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scattering[18]. With PBS,theskindosecanbecontrolledasoneof theobjectives,as
shown above,in the Paretooptimizationand navigation.In order to validate the
accuracyof thedosecalculationat theskin surface,we performedmeasurementsfor
two treatmentfields generatedon a solid water phantom:one mimicking a non-
reconstructedchestwall treatmentwith 3 cm beamrange,and one mimicking a
treatmentwith breast implant with 8 cm range. The accuracyof the skin dose
calculationwasthenassessedusingaMarkusparallelplateion chamber.
2.5Treatment delivery
the institution’s routinepatientquality assurance(QA) procedurefor PBStreatment
was followed for thesePMRT plans. Each PBS field was verified in phantom
measurementby an absolutepoint dose and 2D distributions at two different
depths[21].
the institution’s conventionalproton setupprocessconsistsof: first, the patient is
positionedbasedon tattoospriorly inkedat thetimeof CT-sim;orthogonalX-raysare
thentakenat a specifiedcardinalangle,andthepatientpreciselyplacedat isocenter;
finally, a beamlineX-ray is performedat the treatmentgantryangleto finalize the
setuppositionandensurecorrecttreatment.This techniquewasunfortunatelydeemed
suboptimalfor PMRT patientsasit considersbonyanatomicalfeaturesin thebackof
the patients,suchas the spine,as a surrogatefor the chestwall position[22]. This
resultedin the choice of surfaceimaging as the primary setuptool as the target
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volumeis bothshallowandsuperficial. In our process,thepatientis first setupbased
on tattoosinkedat thetimeof CT scan.A surfaceimagingsystem(brand),usingthree
camerasmountedin a typical triangularpatternas for a LINAC treatmentroom, is
then usedto positionthe patient at isocenter.Shifts are performedusing the couch
with 6-degreeof freedombasedon thetreatmentplanningCT asthereferenceimage.
This referenceprovidesthe ability to monitor any anatomicaldeformationover the
courseof treatment.In oneexemplary case,a shift of thebreastimplantwasdetected
andtheneedfor replanningwasassessedthroughtheacquisitionof anewCT scan.In
order to minimize the effect of breathingmotion on patientpositioning,the motion
tracking function of the surfaceimaging systemwas utilized and the body surface
correspondingto exhalelevel wasselectedfor positioncorrectioncalculations.The
operation tolerancelimits for the setup were 2 mm in translationsand 1.5   in
rotations.Then,a beamlineX-ray is takenat the treatmentgantry angle(30   from
vertical)asa final verification,primarily basedon threeradio-opaquemakersplaced
aroundthe patient’schestwall at positionsselectedandtattooedat the time of CT.
TheX-raysetuptolerancewas1.5mm.This is in considerationof thefact theX-ray is
not gatedto any specificbreathinglevel. For a typical breastpatient,the chestwall
moves about 3 mm in the AP/longitudinal direction at quiet respiration,which
projectsto a motionof 1.5 mm in thebeam’s eyeview with gantryangleat 30   from
vertical. This setup process combining surface and X-ray imaging has been
extensivelystudiedfor a largenumberof patients.The full setupprocessgenerally
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takes10 to 15 minutes.Surfaceimagingresultsin faster and moreaccuratepatient
positioning, along with minimal imaging dose (only final beamlineX-ray). The
techniquesand detailed analyses of the results will be reported separately.
The single PBS treatmentfield usually contains10 to 15 layers with   2 s layer
switchingtime,resultingin a   2 min totalbeamdeliverytime.
2.6Treatment robustnessevaluation
Thetreatmentrobustnesswasevaluatedagainsttwo typesof treatmentperturbations:
breathingmotion and setupuncertainties.For breathingmotion, a 4D-CT scanwas
performedfor a PMRT patientin additionto the regularplanningCT scanat quiet
respiration.Themotionof thechestwall dueto breathingwasfoundmostlyin theAP
direction as expectedwith the maximumamplitudeof 3 mm, which is typical of
breastpatients.The PBS fields generatedon the planningCT scanfor the actual
treatmentweretransferredto the4D CT scanwith dosedistributionsrecomputedon
eachof the10phases.Dosevolumehistograms(DVH) werecomputedfor eachof the
10 phasesaswell asfor the total doseaccumulatedthroughdeformableregistration
[23], mimicking the actual treatment based on the patient’s breathing cycle.
Thesetupuncertaintiesanalysiswasperformedby recomputingthedosedistributions
for a nominal PMRT plan with the samePBS fields but with the introductionof
geometricperturbationsin the isocenterposition and patientbody orientation.The
perturbationswereasfollow: ± 3 mmalongeachtranslationaxis(lateral,longitudinal,
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vertical),± 2   along eachrotation axis (yaw, pitch, roll), and a combinationof all
aforementionedshifts in all 6 directionssimultaneously.DVH were computedfor
eachscenario. Themagnitudeof theseperturbationswasselectedin considerationof
the geometricaccuracyof the surfaceand X-ray imagingsystems,as well as their
operationaltolerancesadoptedduringpatientsetup.
3 Results
3.1Treatment plan quality
As a result of the multi-criteria optimization,the targetcoverageand doseto the
cardiacstructuresareoptimallybalancedthroughintensitymodulation.Likewise,it is
possible to reduce the skin dose to an acceptablelevel, especially in the
supraclavicularnodal region,which is locateddeeperin the body. A nominalPBS
PMRTplanis presentedin figure2.
Thedosestatisticsfor the left-sidedPBSPMRT patientstreatedin the first 4 months
of 2014(in totalof 10)at theinstitutionarepresentedin table1.
3.2Skin dosevalidation
Measurementswereperformedwith a Markusparallelplateionizationchamberat 0,
1, 3, 5, and 7 mm depth, as well as in the centerof the field (13 and 43 mm
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respectively),for both aforementionedtreatmentplans.The resultsarepresentedin
figure3. Thosemeasurementswerein goodagreement(  2 %) with theTPSvalues.
3.3Treatment plan robustness
Therobustnessanalysisresultsagainstsetupuncertaintiesarepresentedin figure4 as
DVH envelopeswhich correspondto the maximumamplitudeof the perturbation
associatedwith thespecifiedshifts,individuallyor simultaneously.As laterdiscussed,
this can be considereda worst casescenario,and any combinationof shifts (± 3
mm,± 2  ) will be containedwithin thoseDVH boundaries.TheDVH of theaverage
distributionbasedon all theseshifts is presentedasa thick dashedline. Overall, the
target coveragefor chestwall, supraclavicular/axilla nodal regions remainsquite
stable,andis thereforerobustagainstsetupuncertainties.Coverageof IMN deviates
substantially more from these shifts, although the minimum dose is still  40
Gy(RBE),evenin theworstcasescenario.ConcerningOARs,DVH distributionsvary
more for thyroid andesophagusthan for others,but all of themarestill considered
clinically acceptable.
Theresultsfor robustnessanalysisagainstbreathingmotionareshownin figure5. As
in figure4, the DVH envelopescorrespondto the maximaldeviationsbased on the
doserecomputationfor eachindividual breathingphase.Thesedeviations,drastically
smaller than the onesobservedin the robustnessanalysisfor setupuncertainties
(figure4), arebelievedto beof no clinical concern.Moreover,it is admittedthat the
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actual treatment would be approximately at the median of these envelopes
statistically,henceremarkablyclose to the planneddosefor the caseillustratedin
figure5, ashighlightedby theaveragedosedistributionDVH basedon the individual
recompuations(thick dashedline).
4 Discussions
PMRT for patientswith potential IMN involvementand yet unfavorablecardiac
anatomy is always a challenge to perform with both acceptable/reliabletarget
coverageand critical organavoidance.Whereasit is necessaryto consider3 to 5
fields in photon/electrontherapy,or a minimum of 2 proton PS fields, in order to
appropriatelycover the numeroustargets,a single PBS field is sufficient. In the
absenceof matchedfields, this highly simplifiesthe treatmentdeliveryandremoves
the hot and cold spotsby meansof intensity modulation.Although the treatment
offersexcellentcardiacstructuresparing,theIMN receivesonaverageameandoseof
48.75 Gy(RBE) for the 10 abovementionedpatients.This representssignificantly
bettertargetcoverage,yetbetterOAR sparing,thanconventionaltherapy[16].
For PMRT by PS,certainsmall areasof skin may receivethe full prescriptiondose
dueto thefixed modulationwidth of thepassivescatteredbeams.Early resultsfor PS
PMRT patients,however,did not showworseskin reactionsthanfor conventionalX-
ray treatment;contrarily, more often superficial dry, rather than moist, squamous
desquamationwereobserved.Predictedrednessof theskin within the treatmentfield
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wasalsonoted[18]. With intensitymodulation,PBSallowsoneto minimizethedose
to the skin while maintaining a uniform target constraint. Given the positive
experiencewith PStreatment,patientsareexpectedto toleratePBStreatmentsequally
well, if not better.It is satisfactoryto seethat the planningsystemcan accurately
computethe skin dose,asconfirmedby the phantommeasurement.Patientspecific
skin dose monitoring is currently under assessmentat the institutionusing
thermoluminescentdosimeters[24], aswell asMOSkindetectors[25].
At the institution, PBS fields for chestwall treatmenttake significantly longer to
deliverthanconventionalscatteredfields:about5 minutesversus1 minute.However,
theoveralltreatmentime,thatis thepatient-in-roomtime,usingPBSis only about15
to 18 minutes,muchshorterthanPStreatment.This is alsogenerallyshorterthanthe
conventionaltreatmentwith 4 photon/electronbeams,which takesabout25 minutes
evenwithout any form of imagingguidance.Optimizationof thecurrentworkflow is
still undergoingfor combineduse of surface and beamlineX-ray imaging, which
couldfurtherreducethesetuptime.
Theplanrobustnessanalyseswereperformedfor asinglepatientonly. Sincethebeam
directionandpatient’ssetupconfigurationaregenerallysimilar,solelytheanatomical
changeswould significantlyaffecttheseresults.This will becharacterizedin a future
detailedstudyusinga largercohortof patients. It shouldbenotedthat themagnitude
of theshiftsandrotationsweredeliberatelylargein orderto testworstcasescenarios
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while, in reality, the setup uncertaintiesare statistically much smaller. This was
highlightedby the averagedosedistributionDVH in the robustnessanalysis.It is
important to point out that the plan robustnessanalysispresentedhere is closely
associatedwith the spotsizesof our currentPBSdelivery systemandcould change
for differentbeamspotsizes.It is generallytrue thatPBStreatmentplanningquality
could differ per institution. Indeed, spot size, source-to-axis distance (SAD),
minimum deliverablecharge,and speed/accuracyof treatmentdelivery are highly
machine specific parameters;besides, the institution’s TPS would dictate the
possibilitiesregardingspot spacing,layer spacing,and the overall quality of the
optimization(notably throughthe presenceor absenceof MCO). Major efforts are
currently underwayat the institutionto reducethe beam spot sizes for all beam
energies including those relevant to chest wall treatment.
A theoreticalplan, presentingsignificant improvements over the plan presentedin
figure2, was producedusing a 3 to 5 mm spot size. A smaller beamspot size,
however,could meana longertreatmenttime. It may alsodegradethe robustnessof
plan againstsetupuncertaintiesand breathingmotion. The implicationsof the spot
size changesand the properbalancebetweenall its effectswill be the subjectsof
futurestudies.
Oneof themostinterestingpotentialimprovementsof PMRT usingprotontherapyis
thepossibilityof treatingthepatientswith theirarmsdownduringtreatmentasshown
16
in figure1(b). Sucha setuppositionis unachievablefor conventionalphotontherapy
which usestangentfields that would treat throughthe arms. The rationalefor such
positionis basedon severalpromisingaspects.For one,it is muchmorecomfortable
thanthearmup positionfor patientswith shouldermobility issuesdueto immediacy
of their surgery,scaring,andotherreasons.Second,patientswith armsup often feel
tired andrelax their armsdownwards,potentiallyaffectingtreatmentto the axillary
nodal regions,while more comfortablearm down positionwill result in the patient
stayingstill for a longerperiodof time. Third, the arm down positionallows larger
clearancebetweenthe patientand the treatmentnozzle,hencereducingthe risk of
hazardouscollision. It could also allow the use of smaller air gapsbetweenthe
treatmentheadandthepatientto helpmaintainthespotsizeandimprovetheoverall
penumbraof thedosedistribution.We haverecentlytreateda patientin thearmdown
positionandarecurrentlycollectingdatafor morepatientsin orderto systematically
assessthisarmsdownsetup.
Althoughonecanforeseeinterplayeffectsbetweenthe beammotionandthepatient
internal motion for such treatment,theseeffects are considerednegligible at the
institutionbasedonpreviouswork on lungtreatmentplanning[26].
5 Conclusion
Wehavedevelopeda treatmentechniquefor PMRTusingpencilbeamscanningwith
intensity modulation.More than 25 PMRT patientshavebeensuccessfullytreated
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at the institution. This treatmenttechniqueis significantlysimplerthanconventional
techniqueswhichusea combinationof photonandelectronbeams,yet with improved
nodalcoverageandsignificantly lesscardiacdose.Althoughthis treatmentrelieson
full imageguidancewith surfaceand X-ray imaging, it is faster than conventional
techniques. Thereare on-going efforts to reachthe optimal PBS PMRT treatment
delivery.Futurestudieswill focuson specificaspectsof thepresentedmethodology,
as well as the short-term side-effects and clinical outcomesof such PBS PMRT
treatment.
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Figure 5: Breathingmotion effect onto a staticPMRT dosedistribution.The solid lines
representheplanneddosewhile theenvelopescorrespondto themaximaldeviations
observedfrom theindividualdoserecomputationson the10 phasesof thepatient4D
scan,andthethick dashedlinesis theaveragedosedistributionDVH basedon all 10
recomputations.
Figure1: PMRTpatient setupat the time of CTscan:(a) conventionalarmsup setupposition,(b) novelarms
down setup position; in both cases,a chin strap and hand grips are used for positioning reproducibility.
Figure2: A protonPBSPMRTplanandits associateddose-volumehistograms(DVH),asintendedfor treatment
at the institution.
Mean (cGy(RBE)) D99 (cGy(RBE)) D1 (cGy(RBE))
Target/OAR Average std dev. Average std dev. Average std dev.
IMN 48.71 1.71 44.30 2.47 51.25 1.28
Lymphnodes(inc.
IMN) 47.39 1.08 42.18 1.93 51.36 1.06
LAD 1.10 0.48 0 - 3.50 0.71
Heart 0.63 0.32 0 - 11.40 5.11
Chestwallskin 47.86 1.09 40.88 2.68 49.57 0.88
Table 1: Dosestatisticsfor 10PBSPMRTpatientstreatedat theinstitution; D99andD1 arethe
dosesin Gy(RBE)receivedby 99% and1 % of thetarget/OARvolume,respectively.
Figure 3: Skindosecomparisonbetween TPS-name computedvaluesand Markus parallel plate ionization
chambermeasurements.
Figure4: ResultingDVHenvelopesbasedon the setuprobustnessanalysis(± 3 mm, ± 2) performedon a PMRT
patient plan (solidline),and comparedto the averagedosedistributionDVH(thick dashedline) basedon the
individualrecompuations.
Figure5: Breathingmotion effect onto a static PMRTdosedistribution.Thesolid linesrepresentthe planned
dose while the envelopes correspond to the maximal deviations observed from the individual dose
recomputationson the 10 phasesof the patient 4D scan,and the thick dashedlines is the averagedose
distributionDVHbasedon all 10 recomputations.
